MorphoSys Announces Extension of Antibody Alliance with Schering-Plough
16 Jun 2009
MorphoSys announced today that Schering-Plough Corporation has triggered its pre-existing option to extend the current collaboration between the two companies for another year
Martinsried, Planegg, Germany | June 16, 2009 | MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Schering-Plough Corporation has triggered its pre-existing option to extend the current collaboration between the two companies for another year. The partnership, which was initiated in May 2006, may be extended by Schering-Plough annually until 2011.
The agreement grants Schering-Plough continued access to MorphoSys's proprietary antibody library HuCAL GOLD at its research site, Schering-Plough Biopharma, in Palo Alto, Calif., and contains options for therapeutic licenses. For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to receive license fees, plus milestone payments relating to the successful advancement of projects in clinical development, and royalties on HuCAL antibodies developed under the agreement. Under the extended agreement, MorphoSys continues to receive annual user fees for access to its HuCAL platform. Further financial details were not disclosed.
"We are pleased with Schering-Plough's decision to extend the current collaboration," comments Dr. Simon Moroney, Chief Executive Officer of MorphoSys. "Today's news demonstrates once more the continued commitment of leading pharmaceutical companies worldwide to our HuCAL technology for their antibody-based drug development programs."
For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0... , gutjahr-loeser@morphosys.comThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it or Mario Brkulj, Senior Manager Corporate Communications & Investor Relations, Tel: +49 (0... , brkulj@morphosys.comThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it
pipelinereview.com |
